Melanoma vaccine results bolster support for California Prop 38

A new experimental melanoma vaccine has sharpened the fight over California’s Proposition 38, with supporters saying the measure would help fund immunology research for cancer and other serious diseases. Backers say the initiative would create a stable funding stream at a time when federal research dollars are uncertain.

Why it matters: - A personalized mRNA vaccine for high-risk melanoma is adding momentum to immunology research that could shape future cancer care. - Supporters say Proposition 38 would provide $8.4 billion for research on cancer, Alzheimer’s, heart disease, Parkinson’s, multiple sclerosis, ALS and other serious illnesses. - Backers say California needs stable research funding as federal support faces cuts and uncertainty.

What happened: - The New York Times reported this week that an experimental personalized mRNA vaccine helped prevent high-risk melanoma from returning or spreading when used with the immunotherapy drug Keytruda. - Researchers described the result as a potentially significant step toward a new generation of cancer treatments that use a patient’s immune system to fight disease. - YES on Prop 38 is using the finding to argue for passage of California’s November ballot measure, the Immunology Medical Research & Cures Initiative.

The details: - Prop 38 is backed by leading cancer advocacy groups, including the Melanoma Research Alliance, Prostate Cancer Foundation, Blood Cancer United, GO2 for Lung Cancer, FORCE: Facing Our Risk of Cancer Empowered, International Myeloma Foundation, Kidney Cancer Association, Bladder Cancer Advocacy Network, Liver Coalition, Head and Neck Cancer Alliance, California Colorectal Cancer Coalition and City of Hope. - Those organizations represent patients and families facing melanoma, prostate, lung, blood, colorectal, liver, kidney, bladder and other cancers. - Gina Carithers, president and CEO of the Prostate Cancer Foundation, said immunotherapy is changing cancer care and that patients cannot afford for research to slow down. - Lila Javan, an immunotherapy patient and cancer survivor, said years of scientific research gave her more hope and more time. - Prop 38 would create a stable funding source for scientists and medical experts working on treatments and cures. - The measure is designed to pay for itself. - Ten percent of all proceeds from licensing immunotherapies would be returned to California to offset the measure’s total costs, including interest. - Any cure or immunotherapy developed would be provided to California patients at a 20 percent discount. - The measure includes a 2 percent cap on state administrative expenses. - Prop 38 requires public disclosure of spending and independent financial audits. - For-profit corporations would not be eligible for grant funding. - YES on Prop 38 says a broad coalition of patient advocates, doctors, nurses, scientists, researchers and medical organizations is supporting the measure. - More information is available at YESon38.com, including a full coalition list and supporter statements. - The campaign also lists social media accounts on LinkedIn, Instagram, Facebook, X and Substack.

Between the lines: - The vaccine story gives supporters a timely example of how immunology research can move from lab work to patient care. - The ballot measure is being framed as both a health policy and funding stability issue. - The financial offsets and audit rules appear aimed at answering voter concerns about cost and oversight.

What's next: - California voters will decide Proposition 38 on the November ballot. - Supporters are expected to keep tying emerging treatment advances to the case for sustained research investment. - The outcome will determine whether the state creates a new long-term funding stream for immunology research and treatment development.

The bottom line: - The melanoma vaccine result is becoming a political argument for Prop 38, with supporters saying the measure could speed the next wave of cancer and disease research.